Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 65

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 7
Chunk 65
---
 and interventional pulmonology to the role. He has authored more than 30 peer-reviewed
publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked
extensively in both academic medicine and private practice, led FDA-approved research programs, and served in national leadership roles
with the American College of Chest Physicians in the areas of interventional pulmonology, lung cancer, and medical ethics.

Patent
Awards

On
June 24, 2025, the Company announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of
patent grant for the company’s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors
on the cell membrane. The Company reported that research and development of this broad-spectrum therapeutic approach will be applied
first to topical application for treatment of skin cancers.

21

On
July 22, 2025, the Company announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum
has been allowed by the Canadian Patent Office. The Canadian patent protects the use of defined antibodies and the porphyrin TCPP to
label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum.

On July 15, 2025, the Company announced it received
notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods
of predicting the likelihood of lung cancer using flow cytometry. The newly allowed Chinese patent protects the use of defined antibodies
and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells
in the sputum.

On May 28, 2025, the Company announced the U.S. Patent
and Trademark Office (USPTO) issued a new patent covering a novel composition and method for selectively killing cancer by targeting the
CD320 and LRP2 receptors on the cell membrane. Company research and development of this broad-spectrum therapeutic approach will be applied
first to topical application for treatment of skin cancers.

Recent
Financings

On
May 7, 2025, the Company completed a public offering of securities for gross proceeds to the Company of $3.25 million, before deducting
agent fees and other estimated expenses payable by the company. The